MIRM

Mirum Pharmaceuticals Inc

120.46

Jul 01 • 04:00PM ET +3.39 (2.90%)

Healthcare Biotechnology USA Mid NASD

Peers: BMRN KRYS RYTM AXSM INCY MDGL PTGX VKTX KROS NBIX

| Held by: VTI IWM XBI VB VXF IWO IBB VBK SCHA VTWO

Scroll to Statements

Index	RUT
Market Cap	7.35B
Enterprise Value	7.28B
Income	-798.84M
Sales	569.61M
Book/sh	3.98
Cash/sh	6.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	372
IPO	Jul 18, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	12.90
P/B	30.27
P/C	19.02
P/FCF	-
EV/EBITDA	-
EV/Sales	12.79
Quick Ratio	1.99
Current Ratio	2.09
Debt/Eq	1.34
LT Debt/Eq	1.33
Option/Short	Yes / Yes

EPS (ttm)	-13.60
EPS next Y	-0.67
EPS next Q	-0.74
EPS this Y	-3229.98%
EPS next Y	95.73%
EPS next 5Y	-
EPS past 3/5Y	51.26% 35.25%
Sales past 3/5Y	89.13% -
EPS Y/Y TTM	-742.29%
Sales Y/Y TTM	50.19%
EPS Q/Q	-4372.49%
Sales Q/Q	43.28%
Earnings	May 06 AMC
EPS/Sales Surpr.	-3576.43% 7.89%

Insider Own	18.53%
Insider Trans	-0.37%
Inst Own	95.56%
Inst Trans	11.29%
ROA	-101.04%
ROE	-335.82%
ROIC	-141.66%
Gross Margin	81.32%
Oper. Margin	-12.31%
Profit Margin	-140.24%
SMA20	14.35%
SMA50	18.26%
SMA200	37.18%
Trades

Shs Outstand	60.93M
Shs Float	49.68M
Short Float	13.91%
Short Ratio	6.89
Short Interest	6.91M
52W High	125.39 -3.93%
52W Low	47.89 151.53%
Volatility	6.00% 4.73%
ATR (14)	5.49
RSI (14)	68.51
Beta	0.48
Rel Volume	1.01
Avg Volume	1.00M
Volume	1,012,624

Perf Week	4.78%
Perf Month	25.05%
Perf Quarter	30.40%
Perf Half Y	50.18%
Perf YTD	52.50%
Perf Year	148.94%
Perf 3Y	365.64%
Perf 5Y	583.27%
Perf 10Y	-
Recom	1.07
Target Price	145.36
Prev Close	117.07
Price	120.46
Change	2.90%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-26	Initiated	Citigroup	Buy	$145
May-19-26	Initiated	Wolfe Research	Outperform	$145
Feb-18-26	Initiated	RBC Capital Mkts	Outperform	$130
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33

Show Previous Ratings

Jun-14-26 04:35PM	Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva (Business Wire)
Jun-11-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.89%
Jun-04-26 08:05AM	Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 (Business Wire)
May-30-26 12:00PM	Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 (Business Wire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
08:05AM	Loading…
May-21-26 08:05AM	Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026 (Business Wire)
May-14-26 04:01PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.26%
May-12-26 11:56PM	Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes (Business Wire)
04:01PM	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering (Business Wire)
08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-06-26 08:29PM	Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary (Moby) -6.50%
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
May-05-26 08:59AM	Idexx Claws Down A Beat As Shares Bound Higher On A Guidance Hike (Investor's Business Daily)
May-04-26 12:59PM	Why This Biotech ETF - The IBD Stock Of The Day - Just Reentered Its Buy Zone (Investor's Business Daily) +9.59%
12:05PM	The $1 Billion-Plus Opportunity That Sent Mirum Pharma Catapulting To A Record (Investor's Business Daily)
08:00AM	Loading…
08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis (Business Wire)
May-03-26 05:00PM	Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 (Business Wire)
Apr-29-26 04:01PM	Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 (Business Wire)
Apr-27-26 08:00AM	Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus (Business Wire)
Mar-16-26 08:00AM	Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI (maralixibat) in Additional Rare Cholestatic Liver Diseases (Business Wire)
Mar-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-26 08:27AM	Mirum Completes Enrollment & Screening in Liver Disease Studies (Zacks)
Mar-05-26 08:00AM	Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus (Business Wire) -5.59%
Feb-26-26 10:50AM	Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues (Zacks) -15.13%
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Feb-25-26 08:00PM	Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:25PM	Mirum Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update (Business Wire)
Feb-23-26 07:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:01PM	Loading…
04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-19-26 06:03AM	ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? (Zacks)
Feb-18-26 04:01PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Feb-10-26 10:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-26 08:51AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire) -5.51%
08:00AM	Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (Business Wire)
Feb-03-26 02:10AM	Mirum doubles down on diversified rare disease strategy (Pharma Voice)
Jan-31-26 03:22PM	Is Mirum Pharmaceuticals on a Strong Path to Profitability? (Motley Fool)
08:15AM	Insiders Are Still Scooping Up Under Armour and WR Berkley Shares (24/7 Wall St.)
Jan-29-26 02:27PM	H.C. Wainwright Raises PT on Mirum Pharmaceuticals For the Second Time In a Span of Two Weeks, Here is Why? (Insider Monkey)
Jan-27-26 06:33AM	Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline (Pharmaceutical Technology)
03:15AM	Is Mirum Pharmaceuticals About to Soar in 2026? (Motley Fool)
Jan-26-26 08:00AM	Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Jan-22-26 09:52PM	Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results (Insider Monkey)
Jan-20-26 09:38AM	CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? (Zacks)
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-13-26 05:04AM	3 Top Growth Stocks to Buy in the First Half of 2026 (Motley Fool)
Jan-12-26 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum (Business Wire)
Jan-09-26 11:55AM	Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals (Business Wire) +6.09%
Jan-07-26 04:01PM	Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.22%
Jan-06-26 08:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-04-26 04:05AM	5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right (Motley Fool)
Dec-30-25 03:07AM	Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now (Motley Fool)
Dec-23-25 01:52PM	This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone (Investor's Business Daily)
Dec-19-25 08:30AM	Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX (Business Wire) +10.61%
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 07:44AM	Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition (Insider Monkey)
Dec-09-25 09:45AM	Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald (TipRanks)
09:42AM	Mirum to buy Bluejay for up to $820m in rare liver disease push (Pharmaceutical Technology)
Dec-08-25 08:31AM	Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay (BioPharma Dive)
08:00AM	Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease (Business Wire)
Dec-04-25 11:30AM	Mirum Pharmaceuticals (MIRM) Up 1.3% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 06:30AM	Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 (Motley Fool)
Dec-02-25 10:15AM	MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study (Zacks)
Dec-01-25 08:10AM	Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome (Business Wire)
Nov-28-25 10:07AM	Biotechs Are On A Big Run, And Two Stocks Have Buy Points (Investor's Business Daily)
Nov-25-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-25 08:10AM	Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire)
Nov-05-25 11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
12:04AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-04-25 05:10PM	Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 04:02PM	Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 (Business Wire)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 07:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

CEO & DirectorMr. Christopher Peetz

Ph.D.Mr. Peter Radovich M.B.A.

M.S.Mr. Eric H. Bjerkholt M.B.A.

Chief Medical OfficerDr. Joanne M. J. Quan M.D.

Chief Technical OfficerDr. Jean-Luc Girardet Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JOLANDA MARIE HOWE	Officer	Jul 01 '26	Proposed Sale	120.00	2,721	326,520		Jul 01 05:24 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jun 17 '26	Sale	101.95	2,594	264,458	5,835	Jun 18 06:39 PM
JOLANDA MARIE HOWE	Officer	Jun 17 '26	Proposed Sale	101.95	2,594	264,458		Jun 17 04:01 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 09 '26	Option Exercise	26.49	2,393	63,391	47,181	Jun 09 09:21 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jun 08 '26	Sale	93.82	5,000	469,077	44,788	Jun 09 09:21 PM
Radovich Peter	PRESIDENT AND COO	Jun 05 '26	Option Exercise	19.19	16,988	326,000	57,260	Jun 08 04:27 PM
ERIC BJERKHOLT	Officer	Jun 08 '26	Proposed Sale	93.81	5,000	469,073		Jun 08 04:20 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Option Exercise	2.94	30,000	88,080	224,309	Jun 02 07:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jun 01 '26	Sale	95.84	30,000	2,875,103	194,309	Jun 02 07:50 PM
Ramasastry Saira	Director	Jun 01 '26	Sale	100.00	3,977	397,700	0	Jun 02 07:50 PM
CHRISTOPHER PEETZ	Officer	Jun 01 '26	Proposed Sale	95.84	30,000	2,875,107		Jun 01 05:33 PM
SAIRA RAMASASTRY	Director	Jun 01 '26	Proposed Sale	100.00	3,977	397,700		Jun 01 04:04 PM
Ramasastry Saira	Director	May 15 '26	Option Exercise	23.51	2,000	47,020	2,000	May 18 08:32 PM
Ramasastry Saira	Director	May 15 '26	Sale	109.47	2,000	218,940	0	May 18 08:32 PM
SAIRA RAMASASTRY	Director	May 15 '26	Proposed Sale	109.47	2,000	218,940		May 15 04:07 PM
Ramasastry Saira	Director	Apr 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Apr 16 08:40 PM
Ramasastry Saira	Director	Apr 15 '26	Sale	96.90	2,000	193,800	0	Apr 16 08:40 PM
SAIRA RAMASASTRY	Director	Apr 15 '26	Proposed Sale	96.90	2,000	193,800		Apr 15 04:11 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	49,788	Mar 17 07:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Mar 16 '26	Sale	91.98	7,287	670,243	18,864	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Option Exercise	23.51	2,000	47,020	2,000	Mar 17 07:30 PM
Ramasastry Saira	Director	Mar 16 '26	Sale	90.76	2,000	181,520	0	Mar 17 07:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 16 '26	Sale	91.98	16,515	1,519,015	40,272	Mar 17 07:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 16 '26	Sale	91.98	4,732	435,239	8,429	Mar 17 07:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 16 '26	Sale	91.98	40,985	3,769,714	194,309	Mar 17 07:30 PM
ERIC BJERKHOLT	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:03 PM
Joanne Quan	Officer	Mar 16 '26	Proposed Sale	92.64	7,287	675,068		Mar 17 07:00 PM
Peter Radovich	Officer	Mar 16 '26	Proposed Sale	92.64	16,515	1,529,950		Mar 17 06:58 PM
Jolanda Howe	Officer	Mar 16 '26	Proposed Sale	92.64	4,732	438,372		Mar 17 06:55 PM
Christopher Peetz	Officer	Mar 16 '26	Proposed Sale	92.64	40,985	3,796,850		Mar 17 06:50 PM
SAIRA RAMASASTRY	Director	Mar 16 '26	Proposed Sale	90.76	2,000	181,520		Mar 16 04:04 PM
Radovich Peter	PRESIDENT AND COO	Mar 06 '26	Option Exercise	15.87	5,912	93,823	26,567	Mar 11 04:05 PM
Ramasastry Saira	Director	Feb 13 '26	Option Exercise	23.51	2,000	47,020	2,000	Feb 17 04:38 PM
Ramasastry Saira	Director	Feb 13 '26	Sale	102.09	2,000	204,180	0	Feb 17 04:38 PM
SAIRA RAMASASTRY	Director	Feb 13 '26	Proposed Sale	102.09	2,000	204,180		Feb 13 04:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '26	Sale	103.30	2,631	271,792	20,655	Feb 03 09:45 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '26	Sale	103.30	9,108	940,888	160,294	Feb 03 09:45 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '26	Sale	103.30	968	99,998	4,503	Feb 03 09:45 PM
Jolanda Howe	Officer	Feb 02 '26	Proposed Sale	103.80	968	100,478		Feb 02 08:29 PM
Peter Radovich	Officer	Feb 02 '26	Proposed Sale	103.80	2,631	273,098		Feb 02 08:25 PM
Christopher Peetz	Officer	Feb 02 '26	Proposed Sale	103.80	9,108	945,410		Feb 02 08:21 PM
Jolanda Howe	Officer	Jan 26 '26	Proposed Sale	96.92	842	81,607		Jan 28 06:47 PM
ERIC BJERKHOLT	Officer	Jan 26 '26	Proposed Sale	96.92	1,053	102,057		Jan 28 06:44 PM
Peter Radovich	Officer	Jan 26 '26	Proposed Sale	96.92	3,143	304,620		Jan 28 06:43 PM
Christopher Peetz	Officer	Jan 26 '26	Proposed Sale	96.92	6,831	662,061		Jan 28 06:40 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 26 '26	Sale	96.19	1,053	101,290	43,741	Jan 27 04:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 26 '26	Sale	96.19	3,143	302,331	23,286	Jan 27 04:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 26 '26	Sale	96.19	842	80,994	3,700	Jan 27 04:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 26 '26	Sale	96.19	6,831	657,088	169,402	Jan 27 04:30 PM
Heron Patrick J	Director	Jan 23 '26	Buy	68.48	131,425	8,999,984	459,010	Jan 27 04:14 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 22 '26	Sale	93.33	926	86,419	3,042	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 22 '26	Sale	93.33	1,822	170,039	12,817	Jan 23 05:30 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Jan 22 '26	Sale	93.33	1,421	132,615	42,127	Jan 23 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 22 '26	Sale	93.33	2,382	222,301	20,679	Jan 23 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 22 '26	Sale	93.33	7,098	662,422	163,733	Jan 23 05:30 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 20 '26	Sale	90.27	6,911	623,853	11,305	Jan 21 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Option Exercise	23.51	2,000	47,020	2,000	Jan 16 04:05 PM
Ramasastry Saira	Director	Jan 15 '26	Sale	90.99	2,000	181,980	0	Jan 16 04:05 PM
SAIRA RAMASASTRY	Director	Jan 15 '26	Proposed Sale	90.99	2,000	181,980		Jan 15 04:02 PM
Ramasastry Saira	Director	Dec 22 '25	Option Exercise	23.51	5,000	117,550	5,000	Dec 23 06:52 PM
Ramasastry Saira	Director	Dec 22 '25	Sale	80.00	5,000	400,000	0	Dec 23 06:52 PM
GREY MICHAEL G	Director	Dec 19 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 23 06:50 PM
GREY MICHAEL G	Director	Dec 19 '25	Sale	78.00	50,000	3,900,000	0	Dec 23 06:50 PM
SAIRA RAMASASTRY	Director	Dec 22 '25	Proposed Sale	80.00	5,000	400,000		Dec 22 04:03 PM
Ramasastry Saira	Director	Dec 18 '25	Option Exercise	23.51	2,000	47,020	2,000	Dec 19 04:15 PM
Ramasastry Saira	Director	Dec 18 '25	Sale	69.73	2,000	139,460	0	Dec 19 04:15 PM
MICHAEL GREY	Director	Dec 19 '25	Proposed Sale	78.00	50,000	3,900,000		Dec 19 04:05 PM
SAIRA RAMASASTRY	Director	Dec 18 '25	Proposed Sale	69.73	2,000	139,460		Dec 18 04:09 PM
GREY MICHAEL G	Director	Dec 01 '25	Option Exercise	2.94	50,000	146,800	50,000	Dec 02 04:04 PM
GREY MICHAEL G	Director	Dec 01 '25	Sale	74.00	50,000	3,700,000	0	Dec 02 04:04 PM
MICHAEL GREY	Director	Dec 01 '25	Proposed Sale	74.00	50,000	3,700,000		Dec 01 04:07 PM
GREY MICHAEL G	Director	Nov 21 '25	Option Exercise	2.94	50,000	146,800	50,000	Nov 25 04:10 PM
GREY MICHAEL G	Director	Nov 21 '25	Sale	70.00	50,000	3,500,000	0	Nov 25 04:10 PM
MICHAEL GREY	Director	Nov 21 '25	Proposed Sale	70.00	50,000	3,500,000		Nov 21 04:09 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Nov 18 '25	Option Exercise	19.24	19,133	368,119	158,034	Nov 20 04:21 PM
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

MIRM

Mirum Pharmaceuticals Inc

Upgrade your Finviz experience